Anesthesia management for emergency laparotomy in a pediatric patient with suspected hereditary angioedema

J Anesth. 2010 Feb;24(1):121-3. doi: 10.1007/s00540-009-0832-6. Epub 2010 Jan 6.

Abstract

Hereditary angioedema (HAE) is caused by complement factor 1 inhibitor (C1-INH) deficiency, and its mode of inheritance is autosomal dominant. We present a case of an 8-year-old patient who required emergency laparotomy after a traffic accident. General anesthesia with tracheal intubation was necessary. The patient's mother and maternal grandmother had been diagnosed with HAE. HAE is associated with high mortality when airway edema is caused by tracheal intubation. It was impossible to rule out HAE preoperatively in the patient. Therefore, we presumed that he had HAE and treated him with pasteurized C1-INH concentrate. The patient underwent laparotomy uneventfully. Several days after the operation, the laboratory data revealed that the perioperative plasma complement 1 q subunit (C1q) protein level and C1-INH function were not lowered. The diagnosis of HAE was not confirmed, but it was not possible to rule out the diagnosis either. The prophylactic use of a C1-INH in this case may be justified, because the procedure was an emergency and because of the high mortality associated with tracheal intubation in patients with HAE.

Publication types

  • Case Reports

MeSH terms

  • Accidents, Traffic*
  • Anesthesia, General*
  • Angioedemas, Hereditary / complications*
  • Angioedemas, Hereditary / drug therapy
  • Angioedemas, Hereditary / genetics
  • Angioedemas, Hereditary / mortality
  • Bicycling*
  • Child
  • Complement C1 Inhibitor Protein / therapeutic use*
  • Edema / etiology
  • Edema / mortality
  • Edema / prevention & control
  • Emergency Treatment
  • Humans
  • Intestinal Perforation / surgery*
  • Intestine, Small / injuries
  • Intestine, Small / surgery*
  • Intubation, Intratracheal / mortality
  • Male
  • Tracheal Diseases / etiology
  • Tracheal Diseases / mortality
  • Tracheal Diseases / prevention & control
  • Treatment Outcome

Substances

  • Complement C1 Inhibitor Protein